US20140234417A1 - Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof - Google Patents

Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof Download PDF

Info

Publication number
US20140234417A1
US20140234417A1 US14/351,325 US201214351325A US2014234417A1 US 20140234417 A1 US20140234417 A1 US 20140234417A1 US 201214351325 A US201214351325 A US 201214351325A US 2014234417 A1 US2014234417 A1 US 2014234417A1
Authority
US
United States
Prior art keywords
tablet
weight
cellulose
salt
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/351,325
Other languages
English (en)
Inventor
Yoshiharu Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140234417(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of US20140234417A1 publication Critical patent/US20140234417A1/en
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INOUE, YOSHIHARU
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
  • Compound (I) 7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (hereunder referred to as Compound (I)) or a salt thereof is known to act as a dopamine D2 receptor partial agonist, a serotonin 5-HT 2A receptor antagonist, and an ⁇ 1 adrenergic receptor antagonist, as well as a serotonin uptake inhibitor (or a serotonin reuptake inhibitor) (Patent Literature 1), and to possess a wide therapeutic spectrum in the treatment of central nervous system diseases (in particular, schizophrenia).
  • Compound (I) or a salt thereof is known to act as a dopamine D2 receptor partial agonist, a serotonin 5-HT 2A receptor antagonist, and an ⁇ 1 adrenergic receptor antagonist, as well as a serotonin uptake inhibitor (or a serotonin reuptake inhibitor) (Patent Literature 1)
  • An object of the present invention is to provide a tablet comprising Compound (I) or a salt thereof as an active ingredient and having excellent disintegration ability, storage stability, and high photostability.
  • the present inventors conducted intensive research to achieve the above object and found that a tablet comprising Compound (I) or a salt thereof as an active ingredient and further comprising lactose, corn starch, microcrystalline cellulose or like excipient; low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium carboxymethyl starch or like disintegrant; and hydroxypropyl cellulose or like binder exhibits excellent disintegration ability and storage stability.
  • the present inventors further found that higher photostability can be attained by applying a coating layer containing a colorant.
  • the present invention was completed through further studies based on this finding, and provides the following items.
  • Item 1 A tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
  • Item 2 The tablet according to Item 1, further comprising:
  • excipient (a) is at least one member selected from the group consisting of sugars, sugar alcohols, starches, and celluloses;
  • the binder (b) is a cellulose derivative
  • the disintegrant (c) is at least one member selected from the group consisting of cellulose derivatives and starch derivatives;
  • the lubricant (d) is a stearate.
  • excipient (a) is at least one member selected from the group consisting of lactose, corn starch, and microcrystalline cellulose;
  • the binder (b) is hydroxypropyl cellulose
  • the disintegrant (c) is at least one member selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and sodium carboxymethyl starch;
  • the lubricant (d) is magnesium stearate.
  • Item 4 The tablet according to Item 2 or 3, wherein the tablet is an uncoated tablet comprising:
  • binder (b) 0.1 to 20% by weight of the binder (b);
  • Item 5 The tablet according to any one of Items 2 to 4, wherein per 1 part by weight of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, the tablet comprises:
  • Item 6 The tablet according to any one of Items 1 to 5, which further comprises a coating layer on the surface thereof.
  • Item 7 The tablet according to Item 6, which further comprises the colorant (e) in the coating layer,
  • the colorant (e) contains an iron oxide
  • the tablet contains 0.1 to 50% by weight of the colorant (e) with respect to the weight of the coating layer.
  • Item 8 The tablet according to any one of Items 1 to 7, which is obtained by forming, into a tablet, a granulated substance obtained through wet granulation.
  • Item 9 The tablet according to any one of Items 1 to 8, wherein the tablet does not contain povidone or crospovidone.
  • Item 10 A method for producing a tablet, the method comprising the steps of:
  • excipient (a) is at least one member selected from the group consisting of sugars, sugar alcohols, starches, and celluloses;
  • the binder (b) is a cellulose derivative
  • the disintegrant (c) is at least one member selected from the group consisting of cellulose derivatives and starch derivatives;
  • the lubricant (d) is a stearate.
  • the tablet of the present invention exhibits excellent disintegration ability, storage stability, and high photostability, so that it can be effectively used in the medical field.
  • FIG. 1 is a graph showing dissolution test results of tablets obtained in Examples 1-1 to 1-3, and Examples 2-1 to 2-3.
  • the tablet of the present invention comprises Compound (I) or a salt thereof as an active ingredient.
  • the tablet of the present invention may be an uncoated tablet having no coating layer applied thereon or a coated tablet having a coating layer on the surface thereof. Furthermore, the tablet of the present invention may be used as an orally disintegrating tablet.
  • Compound (I) or a salt thereof can be produced by a known method, for example, that disclosed in Japanese Unexamined Patent Publication No. 2006-316052 or a method based thereon.
  • Salts of Compound (I) are not particularly limited as long as they are pharmacologically acceptable.
  • metal salts such as alkali metal salts (e.g., sodium salts and potassium salts), alkaline earth metal salts (e.g., calcium salts and magnesium salts), salts of inorganic bases such as ammonium salts, alkali metal carbonates (e.g., lithium carbonate, potassium carbonate, sodium carbonate, and cesium carbonate), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate), and alkali metal hydroxides (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide); salts of organic bases such as tri(lower)alkylamines (e.g., trimethylamine, triethylamine, and N-ethyldiisopropylamine), pyridine, quinoline, piperidine, imidazole, pic
  • Compound (T) or a salt thereof in the above forms may be used singly or in a combination of two or more.
  • the content of Compound (I) or a salt thereof is preferably about 0.05 to 25% by weight, and more preferably about 0.1 to 15% by weight with respect to the weight of the tablet (the weight of an uncoated tablet before applying a coating when the tablet is a coated tablet).
  • the tablet of the present invention preferably comprises additives such as an excipient (a), a binder (b), a disintegrant (c), and a lubricant (d).
  • additives such as an excipient (a), a binder (b), a disintegrant (c), and a lubricant (d).
  • excipients (a) include, for example, sugar such as fructose, white soft sugar, sucrose, powdered sucrose, lactose, powdered hydrogenated maltose starch syrup, and maltose; sugar alcohols such as D-mannitol, D-sorbitol, xylitol, erythritol, maltitol; starch such as wheat starch, corn starch, and potato starch; starch derivatives such as dextrin, beta-cyclodextrin; cellulose or a derivative thereof such as microcrystalline cellulose, powdered cellulose, ethyl cellulose, carboxymethyl cellulose (carmellose), sodium carboxymethyl cellulose (carmellose sodium), and microcrystalline cellulose/carmellose sodium; silicic acid or a salt thereof such as light anhydrous silicic acid, hydrated silicon dioxide, silicon dioxide, calcium silicate, magnesium silicate, and magnesium aluminometasilicate; kaolin; titanium oxide; magnesium oxide
  • excipients (a) may be used singly or in a combination of two or more.
  • sugar, a sugar alcohol, starch, and cellulose are preferable, and lactose, microcrystalline cellulose and corn starch are more preferable.
  • the excipient (a) content is not particularly limited, and is preferably about 10 to 98.5% by weight with respect to the weight of the tablet (when the tablet is coated, the weight of the uncoated tablet), more preferably about 20 to 95%, and still more preferably about 30 to 90% by weight.
  • the excipient (a) amount is not particularly limited, and is preferably about 1 to 2000 parts by weight per 1 part by weight of Compound (I) or a salt thereof, and more preferably about 3 to 1800 parts by weight.
  • the productivity can be improved.
  • binder (b) examples include sucrose; white soft sugar; pregelatinized starch; partially pregelatinized starch; cellulose or a derivative thereof such as microcrystalline cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose (carmellose sodium), hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose (hypromelloses such as hypromellose 2208, hypromellose 2906, and hypromellose 2910); other polysaccharides such as acacia, powdered acacia, agar, powdered agar, guar gum, tragacanth, powdered tragacanth, pullulan, and pectin; acrylic acid based polymer such as metacrylic acid copolymer L, metacrylic acid copolymer LD, metacrylic acid copolymer S,
  • binders (b) may be used singly or in a combination of two or more.
  • a cellulose derivative is preferable, and hydroxypropyl cellulose is more preferable.
  • povidone when povidone is contained as a binder (b), the obtained tablet tends to have reduced photostability and storage stability. Therefore, it is more preferable if this component is substantially not contained.
  • the binder (b) content is not particularly limited, and is preferably about 0.1 to 20% by weight with respect to the weight of the tablet (when the tablet is coated, the weight of the uncoated tablet), and more preferably about 0.5 to 5% by weight.
  • the binder (b) amount is not particularly limited, and is preferably about 0.01 to 100 parts by weight per 1 part by weight of Compound (I) or a salt thereof, and more preferably about 0.1 to 50 parts by weight.
  • disintegrants (c) examples include starch or a derivative thereof such as wheat starch, corn starch, potato starch, partially pregelatinized starch, sodium carboxymethyl starch, and hydroxypropyl starch; cellulose or a derivative thereof such as microcrystalline cellulose, carboxymethyl cellulose (carmellose), calcium carboxymethyl cellulose (carmellose calcium), croscarmellose sodium, and low-substituted hydroxypropyl cellulose; crospovidone; alginic acid; and bentonite. These disintegrants (c) may be used singly or in a combination of two or more.
  • starch or a derivative thereof, and cellulose or a derivative thereof are preferable, and sodium carboxymethyl starch, carmellose calcium, croscarmellose sodium and low-substituted hydroxypropyl cellulose are more preferable. It should be noted that, when crospovidone is contained, the obtained tablet tends to have reduced photostability and storage stability. Therefore, it is more preferable if this component is substantially not contained.
  • low-substituted hydroxypropyl cellulose is a derivative of cellulose including hydroxypropoxyl groups by about 5 to 16%.
  • the amount of the hydroxypropoxyl groups in the low-substituted hydroxypropyl cellulose may be measured by a method listed in, for example, the Japanese Pharmacopeia.
  • the low-substituted hydroxypropyl cellulose may be produced by a method known in the art, or a commercially available product thereof may also be used. Examples of commercially available products of the low-substituted hydroxypropyl cellulose include, but are not limited to, “LH series” and “NBD series” manufactured by Shin-Etsu Chemical Co., Ltd.
  • hydroxypropyl cellulose is a derivative of cellulose including hydroxypropoxyl groups by about 50 to 85%.
  • the amount of the hydroxypropoxyl groups in the hydroxypropyl cellulose may be measured by a method listed in, for example, the Japanese Pharmacopeia.
  • the hydroxypropyl cellulose may be produced by a method known in the art, or a commercially available product thereof may also be used. Examples of commercially available products of the hydroxypropyl cellulose include, but are not limited to, “HPC series” manufactured by Nippon Soda Co., Ltd.; and “Klucel series” manufactured by Hercules Inc.
  • sodium carboxymethyl starch is a derivative of starch including sodium about 6 to 11%.
  • the disintegrant (c) content is not particularly limited, and is preferably about 1 to 25% by weight with respect to the weight of the tablet (when the tablet is coated, the weight of the uncoated tablet), more preferably about 2 to 20% by weight, and still more preferably about 3 to 15% by weight.
  • the disintegrant (c) amount is not particularly limited, and is preferably about 0.1 to 500 parts by weight per 1 part by weight of Compound (I) or a salt thereof, more preferably about 1 to 500 parts by weight, and still more preferably about 1 to 250 parts by weight.
  • the disintegration ability can be improved.
  • lubricants (d) include stearic acid or a salt thereof such as stearic acid, aluminum stearate, calcium stearate, and magnesium stearate; carnauba wax; glycerol ester of fatty acid; hydrogenated oil; yellow beeswax; white beeswax; talc; sodium stearyl fumarate; and polyethylene glycol (macrogols such as macrogol 400, macrogol 600, macrogol 1500, macrogol 4000, and macrogol 6000). These lubricants (d) may be used singly or in a combination of two or more. Among these, stearate, sucrose ester of fatty acid, and hydrogenated oil are preferable, and magnesium stearate is more preferable.
  • the lubricant (d) content is not particularly limited, and is preferably about 0.1 to 10% by weight with respect to the weight of the tablet (when the tablet is coated, the weight of the uncoated tablet), more preferably about 0.2 to 8% by weight, and still more preferably about 0.3 to 7% by weight.
  • the lubricant (d) amount is not particularly limited, and is preferably about 0.01 to 50 parts by weight per 1 part by weight of Compound (I) or a salt thereof, and more preferably about 0.02 to 30 parts by weight.
  • the tablet of the present invention may comprise other components in addition to the excipient (a), the binder (b), the disintegrant (c), and the lubricant (d).
  • other components include various additives applicable to tablets, such as colorants, pH adjusters, preservatives, absorbefacients, taste enhancers, antioxidants, buffers, chelating agents, abrasives, solvents, hardening agents, surfactants, sweeteners, fluidizers, brightening agents, and flavors. Those components may be used in an amount that does not adversely affect the present invention.
  • the tablet of the present invention may be used as an uncoated tablet that comprises the above described components but does not have a coating layer provided thereon.
  • a coated tablet (film-coated tablet) provided with a coating layer is preferable to achieve long-term storage stability and prevent degradation due to light or the like.
  • the coating layer may comprise pharmaceutical additives, such as a coating agent, plasticizer, dispersant, defoaming agent, and the like, usually used for coating (for providing a coat to) orally administrable pharmaceutical preparations.
  • pharmaceutical additives such as a coating agent, plasticizer, dispersant, defoaming agent, and the like, usually used for coating (for providing a coat to) orally administrable pharmaceutical preparations.
  • additives examples include celluloses such as microcrystalline cellulose, methyl cellulose, ethyl cellulose, carmellose sodium, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose (hypromellose) and derivatives thereof; polyethylene glycol (macrogol); polyvinyl alcohol; titanium oxide; and talc. These additives may be used singly or in a combination of two or more.
  • hydroxypropyl methyl cellulose hypermethylcellulose
  • talc hydroxypropyl methyl cellulose
  • titanium oxide titanium oxide
  • polyethylene glycol (macrogol) exists in the coating layer, the obtained tablet tends to have reduced photostability and storage stability. Therefore, it is more preferable if polyethylene glycol (macrogol) is substantially not contained.
  • a colorant (e) is preferably added to the coating agent for coating the tablet.
  • colorants (e) include: iron oxides such as red ferric oxide, yellow ferric oxide, and black iron oxide; titanium oxide; beta-carotene; food blue No. 2; food blue No. 2 aluminium lake; and riboflavin.
  • containing an iron oxide is more preferable from a standpoint of not only adding a color to the tablet but also further improving photostability of the tablet.
  • the colorant (e) may be suitably selected, or used in combination, depending on the color of the coated tablet prepared.
  • titanium oxide is used;
  • a red coated tablet a combination of titanium oxide and red ferric oxide is used;
  • a yellow coated tablet a combination of titanium oxide and yellow ferric oxide is used;
  • a blue coated tablet a combination of titanium oxide and food blue No. 2 aluminium lake is used;
  • an orange coated tablet a combination of titanium oxide, red ferric oxide, and yellow ferric oxide is used;
  • a coated tablet may be made into various colors.
  • the colorant (e) content is preferably about 0.1 to 3% by weight with respect to the total weight of the coated tablet, and about 5 to 50% by weight with respect to the weight of the coating layer of the coated tablet.
  • the amount of a coating layer in tablet that is coated using the coating agent and a colorant (e) that is contained if necessary is preferably about 1 to 10 parts by weight per 100 parts by weight of a tablet (uncoated tablet) before having a coating provided thereon.
  • additives contained in the tablet of the present invention include:
  • an excipient at least one member selected from the group consisting of sugars, sugar alcohols, starches, and celluloses;
  • binder cellulose derivatives
  • disintegrant at least one member selected from the group consisting of cellulose derivatives and starch derivatives;
  • stearates as a lubricant (d), stearates.
  • these additives are preferably used in a combination of: as an excipient (a), at least one member selected from the group consisting of lactose, corn starch, and microcrystalline cellulose; as a binder (b), hydroxypropyl cellulose; as a disintegrant (c), at least one member selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and sodium carboxymethyl starch; and, as a lubricant (d), magnesium stearate.
  • the tablet of the present invention preferably contains each of the components in the content and amount shown below.
  • Tablet Compound (I) or a salt thereof Sugar and/or sugar alcohol: 20 to 80% by weight Starch: 5 to 50% by weight Cellulose: 1 to 30% by weight Hydroxypropyl cellulose: 0.1 to 20% by weight At least one member selected from the group 1 to 25% by weight consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and starch derivatives: Stearate: 0.1 to 10% by weight
  • Sugar and/or sugar alcohol 1 to 1000 parts by weight
  • Starch 1 to 400 parts by weight
  • Cellulose 0.1 to 200 parts by weight
  • Hydroxypropyl cellulose 0.01 to 100 parts by weight
  • Tablet Compound (I) or a salt thereof Lactose: 30 to 60% by weight Corn starch: 10 to 30% by weight Microcrystalline cellulose: 5 to 20% by weight Hydroxypropyl cellulose: 0.5 to 10% by weight At least one member selected from the group 2 to 15% by weight consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and sodium carboxymethyl starch: Magnesium stearate: 0.1 to 10% by weight
  • Lactose 2 to 500 parts by weight Corn starch: 2 to 200 parts by weight
  • Microcrystalline cellulose 0.5 to 100 parts by weight
  • Hydroxypropyl cellulose 0.05 to 50 parts by weight
  • Magnesium stearate 0.05 to 30 parts by weight
  • the tablet of the present invention is a coated tablet
  • preferable examples of the additives contained in the coated tablet include, as the components for an uncoated tablet before coating:
  • an excipient at least one member selected from the group consisting of sugars, sugar alcohols, starches, and celluloses;
  • binder cellulose derivatives
  • disintegrant at least one member selected from the group consisting of cellulose derivatives and starch derivatives;
  • lubricant stearates, and as components for the coating layer:
  • cellulose derivatives cellulose derivatives, talc, titanium oxides and iron oxides as colorant (e).
  • a more preferable combination is a formulation obtained by applying a coating layer on an uncoated tablet; in which, the uncoated tablet contains Compound (I) or a salt thereof, lactose, corn starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, and magnesium stearate, and the coating layer contains hypromellose, talc, titanium oxide, and at least one colorant (e) (iron oxide) selected from the group consisting of red ferric oxide, yellow ferric oxide, and black iron oxide.
  • Compound (I) or a salt thereof lactose, corn starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, and magnesium stearate
  • the coating layer contains hypromellose, talc, titanium oxide, and at least one colorant (e) (iron oxide) selected from the group consisting of red ferric oxide, yellow ferric oxide, and black iron oxide.
  • Compound (I) or a salt thereof 0.05 to 20% by weight
  • Sugar and/or sugar alcohol 20 to 80% by weight
  • Starch 5 to 50% by weight
  • Cellulose 1 to 30% by weight
  • Hydroxypropyl cellulose 0.1 to 20% by weight
  • Cellulose derivative 1 to 6% by weight
  • Talc 0.1 to 1% by weight
  • Titanium oxide 0.1 to 2% by weight
  • Iron oxide 0.01 to 1% by weight
  • Lactose 1 to 1000 parts by weight
  • Starch 1 to 400 parts by weight
  • Cellulose 0.1 to 200 parts by weight
  • Hydroxypropyl cellulose 0.01 to 100 parts by weight
  • Stearate 0.01 to 50 parts by weight
  • Hypromellose 0.1 to 50 parts by weight
  • Talc 0.01 to 10 parts by weight Titanium oxide: 0.01 to 20 parts by weight
  • Iron oxide 0.0005 to 5 parts by weight
  • Compound (I) or a salt thereof 0.1 to 15% by weight Lactose: 30 to 60% by weight Corn starch: 10 to 30% by weight Microcrystalline cellulose: 5 to 20% by weight Hydroxypropyl cellulose: 0.5 to 10% by weight At least one member selected from the group 2 to 15% by weight consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and sodium carboxymethyl starch: Magnesium stearate: 0.1 to 10% by weight
  • Hypromellose 1.5 to 4% by weight
  • Talc 0.2 to 0.5% by weight
  • Titanium oxide 0.2 to 1% by weight
  • Iron oxide 0.02 to 0.5% by weight
  • Lactose 2 to 500 parts by weight Corn starch: 2 to 200 parts by weight
  • Microcrystalline cellulose 0.5 to 100 parts by weight Hydroxypropyl cellulose: 0.05 to 50 parts by weight At least one member selected from the 1 to 250 parts by weight group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, and sodium carboxymethyl starch:
  • Magnesium stearate 0.05 to 30 parts by weight
  • Hypromellose 0.2 to 40 parts by weight
  • Talc 0.02 to 8 parts by weight Titanium oxide: 0.02 to 15 parts by weight Iron oxide: 0.001 to 2.5 parts by weight
  • the method for producing the tablet of the present invention is not particularly limited; for example, the tablet of the present invention can be produced by a step of forming into a tablet a mixture containing Compound (I) or a salt thereof, and components other than Compound (I) or a salt thereof necessary to form a tablet (i.e., an excipient (a), a binder (b), a disintegrant (c), a lubricant (d) and the like).
  • the tablet of the present invention can be produced by the method comprising: granulating a mixture containing Compound (I) or a salt thereof, an excipient (a), a binder (b), and a disintegrant (c), and further mixing thereto a lubricant (d); and forming the obtained mixture into a tablet.
  • the granulation method used for forming the granulated substance into a tablet is not particularly limited. Examples thereof include dry granulation methods and wet granulation methods (e.g., a fluidized-bed granulation method, and a knead-granulation method). Among these, wet granulation methods are preferably used for the production, from a standpoint of being able to uniformly mix the active ingredient and other components in the tablet, and being able to obtain a tablet whose components are uniformly distributed therein.
  • Examples of the tablet forming methods include tableting, such as direct compression tableting, dry tableting, wet tableting, and external lubrication tableting.
  • the coated tablet of the present invention can be produced by mixing a coating agent, a colorant (e), and a liquid medium; spraying the obtained liquid mixture on the surface of the uncoated tablet obtained by the method described above; and successively drying it.
  • liquid medium e.g., a dispersion medium
  • examples of the liquid medium used in the above described step include: water; methanol, ethanol, isopropanol, and like lower alcohols; acetone, methyl ethyl ketone, and like ketones; dichloromethane, dichloroethane, chloroform, carbon tetrachloride and like halogenated hydrocarbons; and mixtures of these solvents.
  • the tablet of the present invention preferably comprises Compound (I), which is an active ingredient, or a salt thereof in an amount of about 0.05 to 25 mg calculated as Compound (I).
  • the dose of the tablet of the present invention is suitably selected according to the intended use; the patient's age, sex, and other conditions; the severity of the disease; and the like.
  • the dose is preferably selected so that the amount of Compound (I) (i.e., the active ingredient) or a salt thereof taken is about 0.05 to 6 mg per day calculated as Compound (I).
  • Uncoated tablets (a tablet not provided with a coating layer) of Compound (I) were produced using the components and amounts shown in Table 1, by following the procedures described below.
  • Compound (I) lactose, corn starch, microcrystalline cellulose (CEOLUS PH-301), and low-substituted hydroxypropylcellulose (LH-11, manufactured by Shin-Etsu Chemical Co., Ltd., hydroxypropoxyl groups content: 10.0 to 12.9%) were weighed and mixed. A separately prepared aqueous solution of hydroxypropylcellulose was added to the powder mixture, followed by wet kneading granulation. After drying and sizing the result, magnesium stearate was added thereto and mixed. The resulting mixture was compressed using a single tableting machine equipped with a punch of diameter 6.5 mm in such a manner that the weight of the tablet became 100 mg, obtaining uncoated tablets containing 10 mg of Compound (I) per tablet.
  • LH-11 manufactured by Shin-Etsu Chemical Co., Ltd., hydroxypropoxyl groups content: 10.0 to 12.9%
  • Compound (I) lactose, corn starch, microcrystalline cellulose, and croscarmellose sodium were weighed and mixed. A separately prepared aqueous solution of hydroxypropylcellulose was added to the powder mixture, followed by wet kneading granulation. After drying and sizing the result, magnesium stearate was added thereto and mixed. The resulting mixture was compressed using a single tableting machine equipped with a punch of diameter 6.5 man in such a manner that the weight of the tablet became 100 mg, obtaining uncoated tablets containing 10 mg of Compound (I) per tablet.
  • Compound (I) lactose, corn starch, microcrystalline cellulose, and sodium carboxymethyl starch were weighed and mixed. A separately prepared aqueous solution of hydroxypropylcellulose was added to the powder mixture, followed by wet kneading granulation. After drying and sizing the result, magnesium stearate was added thereto and mixed. The resulting mixture was compressed using a single tableting machine equipped with a punch of diameter 6.5 nm in such a manner that the weight of the tablet became 100 mg, obtaining uncoated tablets containing 10 mg of Compound (I) per tablet.
  • Table 2 shows the tablet properties of uncoated tablets obtained in Examples 1-1 to 1-3.
  • disintegration test results show the measurement results of six tablets of each Example.
  • the test was performed using water as a test liquid according to the disintegration test of the Japanese Pharmacopeia (without an auxiliary disk).
  • the uncoated tablets produced in Examples 1-1 to 1-3 each having a weight of 100 mg and containing 10 mg of Compound (I) were subjected to coating by spraying a coating liquid comprising the coating layer components whose amounts are shown in Table 3 thereby obtaining coated tablets.
  • Example Example Components (mg) 2-1 2-2 2-3 Uncoated tablet Example Example Example 1-1 1-2 1-3 Weight of uncoated tablet 100.0 100.0 100.0 (mg) Coating layer (mg) Hypromellose 2.07 2.07 2.07 Macrogol 6000 0.30 0.30 0.30 Talc 0.30 0.30 0.30 Titanium oxide 0.30 0.30 0.30 Yellow ferric oxide 0.03 0.03 0.03 Weight of coating layer (mg) 3.0 3.0 3.0 Weight of coated tablet (mg) 103.0 103.0 103.0
  • Example 2-1 Example 2-2
  • FIG. 1 shows the results.
  • the dissolution test results show the average values of the measurement results of two tablets of each Example.
  • the dissolution test was performed in accordance with the dissolution test method (paddle method; 50 rpm) of the Japanese Pharmacopoeia, using a disodium hydrogenphosphate-citric acid buffer solution (900 mL) with pH 4.5 as a test liquid.
  • the dissolution test results confirm excellent dissolution profiles of the uncoated tablets produced in Examples 1-1 to 1-3 and the coated tablets produced in Examples 2-1 to 2-3.
  • Example 3-1 Compound (I) 0.25 Lactose 48.15 Corn starch 20.0 Microcrystalline cellulose 10.0 Low-substituted hydroxypropylcellulose 10.0 Hydroxypropylcellulose 1.0 Magnesium stearate 0.6 Weight of uncoated tablet (mg) 90.0
  • Example 3-1 The uncoated tablets produced in Example 3-1 each having a weight of 90 mg and containing 0.25 mg of Compound (I) were subjected to coating by spraying a coating liquid comprising the coating layer components whose amounts are shown in Table 7 thereby obtaining coated tablets.
  • Example 3-1 a stability test was performed for the uncoated tablets produced in Example 3-1 and the coated tablets produced in Examples 3-2 to 3-9 under the storage conditions of light irradiation (visible light: total illuminance of 1.8 ⁇ 10 6 lux ⁇ hr; ultraviolet light: total intensity of 300 W ⁇ hr/m 2 ) and an open system at 40° C./75% RH (three months, six months), i.e., conditions as or more severe as those of Examples 1-1 to 1-3 and Examples 2-1 to 2-3.
  • the contents of impurity after the storage in each condition were measured. Table 8 shows the results.
  • Coated tablets of Compound (I) of Examples 4-1 to 4-13 that comprise the components and amounts shown in Table 9 were produced in the same manner as in Example 3-2.
  • the tablet of the present invention comprising benzothiophen compound (I) or a salt thereof has excellent disintegration ability, storage stability, and photostability. Therefore, the tablet of the present invention is highly usable in the medical field.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Supply Of Fluid Materials To The Packaging Location (AREA)
  • Basic Packing Technique (AREA)
US14/351,325 2011-10-14 2012-10-12 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof Abandoned US20140234417A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011227057 2011-10-14
JP2011-227057 2011-10-14
PCT/JP2012/076415 WO2013054872A1 (ja) 2011-10-14 2012-10-12 ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/076415 A-371-Of-International WO2013054872A1 (ja) 2011-10-14 2012-10-12 ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/019,874 Continuation US20160158227A1 (en) 2011-10-14 2016-02-09 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1h-quinolin-2-one or a salt thereof

Publications (1)

Publication Number Publication Date
US20140234417A1 true US20140234417A1 (en) 2014-08-21

Family

ID=48081918

Family Applications (8)

Application Number Title Priority Date Filing Date
US14/351,325 Abandoned US20140234417A1 (en) 2011-10-14 2012-10-12 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US15/019,874 Abandoned US20160158227A1 (en) 2011-10-14 2016-02-09 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1h-quinolin-2-one or a salt thereof
US15/444,113 Abandoned US20170165258A1 (en) 2011-10-14 2017-02-27 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US15/713,427 Active US10307419B2 (en) 2011-10-14 2017-09-22 Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
US16/383,488 Abandoned US20190240215A1 (en) 2011-10-14 2019-04-12 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US17/061,394 Abandoned US20210023078A1 (en) 2011-10-14 2020-10-01 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US17/653,838 Abandoned US20220331311A1 (en) 2011-10-14 2022-03-07 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US18/543,053 Pending US20240277703A1 (en) 2011-10-14 2023-12-18 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/019,874 Abandoned US20160158227A1 (en) 2011-10-14 2016-02-09 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1h-quinolin-2-one or a salt thereof
US15/444,113 Abandoned US20170165258A1 (en) 2011-10-14 2017-02-27 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US15/713,427 Active US10307419B2 (en) 2011-10-14 2017-09-22 Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
US16/383,488 Abandoned US20190240215A1 (en) 2011-10-14 2019-04-12 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US17/061,394 Abandoned US20210023078A1 (en) 2011-10-14 2020-10-01 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US17/653,838 Abandoned US20220331311A1 (en) 2011-10-14 2022-03-07 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US18/543,053 Pending US20240277703A1 (en) 2011-10-14 2023-12-18 Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Country Status (32)

Country Link
US (8) US20140234417A1 (el)
EP (1) EP2767285B1 (el)
JP (2) JP6084161B2 (el)
KR (1) KR102072371B1 (el)
CN (2) CN107397730A (el)
AP (1) AP2014007564A0 (el)
AR (1) AR088319A1 (el)
AU (1) AU2012321723C1 (el)
BR (1) BR112014008603A2 (el)
CA (1) CA2851588C (el)
CL (1) CL2014000909A1 (el)
CO (1) CO6950480A2 (el)
CY (1) CY1122460T1 (el)
DK (1) DK2767285T3 (el)
EA (1) EA032930B1 (el)
ES (1) ES2762479T3 (el)
HR (1) HRP20200037T1 (el)
HU (1) HUE047493T2 (el)
IL (1) IL231513B (el)
IN (1) IN2014DN02055A (el)
JO (1) JO3753B1 (el)
LT (1) LT2767285T (el)
MX (1) MX2014004135A (el)
MY (1) MY173370A (el)
PL (1) PL2767285T3 (el)
PT (1) PT2767285T (el)
SG (2) SG10201608412SA (el)
SI (1) SI2767285T1 (el)
TW (1) TWI634908B (el)
UA (1) UA114411C2 (el)
WO (1) WO2013054872A1 (el)
ZA (1) ZA201402333B (el)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180237445A1 (en) * 2017-02-23 2018-08-23 Boehringer Ingelheim International Gmbh Medical Use of Compound III
US20190030033A1 (en) * 2016-02-19 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
US10517951B2 (en) 2012-04-23 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
USRE48059E1 (en) 2005-04-14 2020-06-23 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US11123300B2 (en) * 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US11406600B2 (en) 2017-11-22 2022-08-09 Sawai Pharmaceutical Co., Ltd. Anhydrous dasatinib-containing preparation
EP4015002A4 (en) * 2019-08-13 2023-06-07 Otsuka Pharmaceutical Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC COMPOUND

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JP5936732B1 (ja) * 2015-03-05 2016-06-22 日本カラコン合同会社 フィルムコーティング組成物
CN105106142B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法
US20190201345A1 (en) * 2016-06-28 2019-07-04 Japan Antivirus Res. Inst., Ltd. Excipient and tablet
TWI728156B (zh) * 2016-07-27 2021-05-21 日商日本臟器製藥股份有限公司 含有胺甲蝶呤之膜衣錠
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
CN106496206A (zh) * 2016-08-31 2017-03-15 安徽省润生医药股份有限公司 一种依匹哌唑新的制备方法
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
CN112168794A (zh) * 2020-10-27 2021-01-05 浙江诺得药业有限公司 一种布瑞哌唑片的制备方法
TWI820674B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑物口腔薄膜劑、其製備方法及用途
EP4374856A1 (en) 2022-11-23 2024-05-29 Sanovel Ilac Sanayi Ve Ticaret A.S. A process for tablets comprising brexpiprazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US20080187582A1 (en) * 2005-03-01 2008-08-07 Patrice Guitard Pharmaceutical Composition Comprising an Indolylmaleimide Derivative

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353659A1 (en) * 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
KR101027570B1 (ko) * 2002-05-03 2011-04-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
CA2531694A1 (en) * 2003-06-09 2004-12-09 Dow Global Technologies Inc. Stabilized organoborane polymerization initiators and polymerizable compositions
JP2006061067A (ja) * 2004-08-26 2006-03-09 Asahi Kasei Life & Living Corp 酸素インジケーター
CA2600542A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
JP4806595B2 (ja) * 2006-07-05 2011-11-02 富士フイルム株式会社 固体撮像素子駆動装置及びデジタルカメラ
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008106059A1 (en) * 2007-02-26 2008-09-04 Merck & Co., Inc. Formulations for cathepsin k inhibitors
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
EP2209501B1 (en) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan composition containing mannitol and microcrystalline cellulose
JP5463564B2 (ja) * 2009-05-22 2014-04-09 国立大学法人信州大学 耐熱性及び耐塩性セルラーゼ製剤
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JOP20120083B1 (ar) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
US9839684B2 (en) 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US20080187582A1 (en) * 2005-03-01 2008-08-07 Patrice Guitard Pharmaceutical Composition Comprising an Indolylmaleimide Derivative

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48059E1 (en) 2005-04-14 2020-06-23 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US11097007B2 (en) 2012-04-23 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US10517951B2 (en) 2012-04-23 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US11638757B2 (en) 2012-04-23 2023-05-02 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US12016927B2 (en) 2012-04-23 2024-06-25 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US20190030033A1 (en) * 2016-02-19 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
US10786507B2 (en) * 2016-02-19 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
US11123300B2 (en) * 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US10919898B2 (en) * 2017-02-23 2021-02-16 Boehringer Ingelheim International Gmbh Medical use of compound III
US20180237445A1 (en) * 2017-02-23 2018-08-23 Boehringer Ingelheim International Gmbh Medical Use of Compound III
US11406600B2 (en) 2017-11-22 2022-08-09 Sawai Pharmaceutical Co., Ltd. Anhydrous dasatinib-containing preparation
EP4015002A4 (en) * 2019-08-13 2023-06-07 Otsuka Pharmaceutical Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC COMPOUND
EP4015001A4 (en) * 2019-08-13 2023-06-14 Otsuka Pharmaceutical Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
US20210023078A1 (en) 2021-01-28
US20190240215A1 (en) 2019-08-08
UA114411C2 (uk) 2017-06-12
US20240277703A1 (en) 2024-08-22
AR088319A1 (es) 2014-05-28
AU2012321723C1 (en) 2017-11-02
US20170165258A1 (en) 2017-06-15
AU2012321723B2 (en) 2017-07-20
US20180008600A1 (en) 2018-01-11
BR112014008603A2 (pt) 2017-04-18
IN2014DN02055A (el) 2015-05-15
WO2013054872A1 (ja) 2013-04-18
CN103889425A (zh) 2014-06-25
TW201318651A (zh) 2013-05-16
KR102072371B1 (ko) 2020-02-03
SG2014013783A (en) 2014-06-27
JP2017088610A (ja) 2017-05-25
PL2767285T3 (pl) 2020-04-30
MY173370A (en) 2020-01-21
CA2851588A1 (en) 2013-04-18
SI2767285T1 (sl) 2020-03-31
CO6950480A2 (es) 2014-05-20
CN107397730A (zh) 2017-11-28
EA032930B1 (ru) 2019-08-30
CA2851588C (en) 2019-07-02
PT2767285T (pt) 2020-01-21
EP2767285B1 (en) 2019-11-27
EP2767285A4 (en) 2015-03-11
ZA201402333B (en) 2015-07-29
CN103889425B (zh) 2018-08-03
JPWO2013054872A1 (ja) 2015-03-30
US10307419B2 (en) 2019-06-04
LT2767285T (lt) 2020-02-10
EA201490783A1 (ru) 2014-07-30
HRP20200037T1 (hr) 2020-03-20
EP2767285A1 (en) 2014-08-20
CL2014000909A1 (es) 2014-11-21
AU2012321723A1 (en) 2014-05-15
KR20140075754A (ko) 2014-06-19
JO3753B1 (ar) 2021-01-31
US20220331311A1 (en) 2022-10-20
US20160158227A1 (en) 2016-06-09
JP6084161B2 (ja) 2017-02-22
NZ622639A (en) 2015-11-27
TWI634908B (zh) 2018-09-11
IL231513A0 (en) 2014-04-30
HUE047493T2 (hu) 2020-04-28
MX2014004135A (es) 2014-07-24
CY1122460T1 (el) 2021-01-27
DK2767285T3 (da) 2020-01-27
AP2014007564A0 (en) 2014-04-30
ES2762479T3 (es) 2020-05-25
IL231513B (en) 2020-01-30
SG10201608412SA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US20240277703A1 (en) Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
TW201639575A (zh) 固形製劑
US20190046452A1 (en) Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
JP4972563B2 (ja) 新規なフィルムコーティング錠
NZ622639B2 (en) TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
TW202038918A (zh) 醫藥組合物
US20190054026A1 (en) Solid preparation
OA17035A (en) Tablet Comprising 7-[4-(4-benzo[b]thiophen4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof.
EP3251669B1 (en) Solid composition of pyrrole carboxamide
WO2021240352A1 (en) Pharmaceutical formulations of pilocarpine r-(+)-lipoate
CA3237792A1 (en) Pharmaceutical composition having excellent dissolution properties
WO2019203746A2 (en) The pharmaceutical combination comprising raloxifene and aripiprazole

Legal Events

Date Code Title Description
AS Assignment

Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INOUE, YOSHIHARU;REEL/FRAME:033930/0447

Effective date: 20140402

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION